CIRCULATING TUMOR CELL DIAGNOSTICS FOR THERAPY TARGETING PD-L1The disclosure provides a method for determining if a subject afflicted with cancer is a candidate for Programmed Death Ligand-1 (PD-L1) targeted immunotherapy, which method comprises (a) providing a liquid biopsy sample obtained from the...
At a cut-off level of 5% PD-L1 positive tumor cells, PD-L1 positivity was seen in 6.3% of 633 clear cell RCC (ccRCC), 18.2% of 165 papillary RCC, 18.8% of 64 chromophobe RCC, and 41.7% of 103 oncocytomas. In ccRCC, PD-L1 positivity was significantly linked to high ISUP (p <...
and TRAPs isolated from these samples could also polarize monocytes to an M2-like phenotype with increased expression of PD-L1, CD163 and IL-10, decreased expression of HLA-DR, and T cell-suppressive function.These findings suggest the TRAPs-PD-L1 axis as a major driver of immunosuppression ...
Immunotherapies targeting PD-1/PD-L1 are now widely used in the clinic to treat a variety of malignancies. While most of the research on T cell exhaustion and PD-1 blockade has been focused on conventional αβ T cells, the contribution of innate-like T
Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway blockade is a promising new cancer therapy. Although PD-1/PD-L1 treatment has yielded clinical benefits in several types of cancer, further studies are required to clarif
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune
作为液体活检的三驾马车之一,循环肿瘤细胞(circulating tumor cell,简称CTC)在临床和科研领域都掀起过研究热潮。然而,数量稀少、获取困难、检测可重复性不高等问题始终限制着CTC相关技术的应用。2016年底,CTC领域的核心玩家强生更是出售了旗下所有与Cellsearch® CTC系统相关的资产和业务,这再次为CTC的应用前景蒙上了一...
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, bloc...
PD-1/PD-L1 axis It is well known that tumors can suppress immune responses, and negative regulatory pathways, or checkpoints, play key roles in tumors escaping detection of immune system [9], [10], [11]. Cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD...
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci. Rep. 2016; 6:... T Kato - 《International Journal of Urology》 被引量: 0发表: 2022年 Soluble PD-L1 changes in advanced non-small cell lung cancer pati...